Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News · Oct 23, 2026 · 21m · transcript

Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro, citing "lack of assurance of sterility," and FDA classified the recall as Class II. A bipartisan group of senators led by Sen. Jim Banks wrote to the acting FDA commissioner on October 14, 2026, urging a crackdown on vendors using "for research use only" labels to sell retatrutide, Eli Lilly's investigational drug that is not FDA-approved, and citing a 265% rise in poisonings tied to…